An Exploratory Study of the Immunological Effects of Vemurafenib and Cobimetinib, Administered Alone and in Combination, in Subjects With Advanced BRAF V600E/K Mutant Melanoma
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 17 Nov 2016
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Registrational
- 14 Nov 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Nov 2016.
- 14 Nov 2016 Planned initiation date changed from 1 Apr 2015 to 1 Aug 2015.
- 14 Nov 2016 Status changed from recruiting to withdrawn prior to enrolment.